US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TuHURA Biosciences, Inc.

3.90

-0.0200-0.51%

Volume:58.02K

Turnover:228.46K

Market Cap:170.35M

PE:-3.21

High:4.05

Open:4.00

Low:3.81

Close:3.92

Loading ...

Overview Company News Filings

TuHURA Biosciences Inc. Announces Initiation of Phase 1b/2a Trial for IFx-Hu2.0 as Adjunctive Therapy in Metastatic Merkel Cell Carcinoma

Tuhura Biosciences Inc - FDA Agreement Reached to Lift Partial Clinical Hold on Phase 3 Trial of Ifx-2.0

THOMSON REUTERS

Tuhura Biosciences, Inc. Initiates Phase 1B/2a Study of Ifx-Hu2.0 as an Adjunctive Therapy to Keytruda® (Pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (Mccup)

THOMSON REUTERS

Tuhura Biosciences Inc: Anticipates Initiating Phase 3 Registrational Trial of Ifx-2.0 in Q2

THOMSON REUTERS

Press Release: TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

BRIEF-Tuhura Biosciences Appoints Dr. Bertrand Le Bourdonnec As Executive Vice President

Tuhura Biosciences, Inc. Appoints DR. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

THOMSON REUTERS

Press Release: TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

TuHURA Biosciences Is Maintained at Buy by HC Wainwright & Co.

TuHURA Biosciences price target lowered to $12 from $13 at H.C. Wainwright

TuHURA Biosciences FY24 EPS ($1.21) Up From ($2.47) YoY

Press Release: TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

TuHURA Biosciences appoints Craig Tendler to board of directors

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors

ACCESS Newswire

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

ACCESS Newswire

TuHURA Biosciences Initiated at Buy by HC Wainwright & Co.

HC Wainwright Initiates TuHURA Biosciences at Buy With $13 Price Target

MT Newswires Live

TuHURA Biosciences initiated with a Buy at H.C. Wainwright

Tuhura Biosciences, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS

TuHURA Biosciences Inc expected to post a loss of 13 cents a share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/HURA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HURA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","market":"US","secType":"STK","nameCN":"TuHURA Biosciences, Inc.","latestPrice":3.9,"timestamp":1746475200000,"preClose":3.92,"halted":0,"volume":58024,"delay":0,"floatShares":21286907,"shares":43680397,"eps":-1.213628,"marketStatus":"Pre-Mkt","change":-0.02,"latestTime":"05-06 07:28:55 EDT","open":4,"high":4.05,"low":3.81,"amount":228455.487204,"amplitude":0.061224,"askPrice":4.34,"askSize":100,"bidPrice":3.59,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.213628,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746538200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":3.9,"postHourTrading":{"tag":"盘后","latestPrice":3.9,"preClose":3.9,"latestTime":"17:13 EDT","volume":11,"amount":43.35,"timestamp":1746479591873},"volumeRatio":0.4682678028435661},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","floatShares":21286907,"roa":"-90.68%","roe":"-332.67%","lyrEps":-1.213628,"volumeRatio":0.4682678028435661,"shares":43680397,"dividePrice":0,"high":4.05,"amplitude":0.061224,"preClose":3.92,"low":3.81,"week52Low":1.8,"pbRate":"11.90","week52High":14.595,"institutionHeld":0,"latestPrice":3.9,"eps":-1.213628,"divideRate":0,"volume":58024,"delay":0,"ttmEps":-1.213628,"open":4,"prevYearClose":4.09,"prevWeekClose":3.92,"prevMonthClose":3.78,"prevQuarterClose":3.23,"fiveDayClose":3.97,"twentyDayClose":3.38,"sixtyDayClose":4.46},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HURA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533760586","title":"TuHURA Biosciences Inc. Announces Initiation of Phase 1b/2a Trial for IFx-Hu2.0 as Adjunctive Therapy in Metastatic Merkel Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2533760586","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533760586?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:01","pubTimestamp":1746446495,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Inc. Announces Initiation of Phase 1b/2a Trial for IFx-Hu2.0 as Adjunctive Therapy in Metastatic Merkel Cell Carcinoma. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on May 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nNDLlzZBm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2533858625","title":"Tuhura Biosciences Inc - FDA Agreement Reached to Lift Partial Clinical Hold on Phase 3 Trial of Ifx-2.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2533858625","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533858625?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446408,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nTUA17NP03:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2533586828","title":"Tuhura Biosciences, Inc. Initiates Phase 1B/2a Study of Ifx-Hu2.0 as an Adjunctive Therapy to Keytruda® (Pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (Mccup)","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586828","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586828?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446408,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nTUA17NP03:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2533586211","title":"Tuhura Biosciences Inc:  Anticipates Initiating Phase 3 Registrational Trial of Ifx-2.0 in Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586211","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586211?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446408,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nTUA17NP03:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2525891539","title":"Press Release: TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2525891539","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525891539?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:18","pubTimestamp":1744114680,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting. TAMPA, Fla., April 8, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that an abstract highlighting Kineta Inc.'s novel KVA12123 antibody and an abstract from Moffitt Cancer Center scientists examining the mechanisms of Company's IFx-Hu2.0 therapy in advanced melanoma have been selected for poster presentation at the American Association for Cancer Research  Annual Meeting 2025, taking place April 25-30, 2025, at the McCormick Place Convention Center in Chicago, IL.TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda  compared to K","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4232","HURA","KANT","BK4022","BK4139"],"gpt_icon":0},{"id":"2525043506","title":"BRIEF-Tuhura Biosciences Appoints Dr. Bertrand Le Bourdonnec As Executive Vice President","url":"https://stock-news.laohu8.com/highlight/detail?id=2525043506","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525043506?lang=en_us&edition=fundamental","pubTime":"2025-04-07 21:02","pubTimestamp":1744030944,"startTime":"0","endTime":"0","summary":"BRIEF-Tuhura Biosciences Appoints Dr. Bertrand Le Bourdonnec As Executive Vice PresidentApril 7 (Reuters) - TuHURA Biosciences Inc HURA.O:TUHURA BIOSCIENCES, INC. APPOINTS DR. BERTRAND LE BOURDONNEC A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nTUA19NJVQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2525010550","title":"Tuhura Biosciences, Inc. Appoints DR. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2525010550","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525010550?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:24","pubTimestamp":1744028658,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nTUA19NJVQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2525010694","title":"Press Release: TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2525010694","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525010694?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:24","pubTimestamp":1744028640,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management. Proven 20-year career in drug discovery and development track record leading to 12 pre-clinical/clinical candidates and 7 investigational new drug / clinical trial applications. Extensive knowledge in the biochemistry and pharmacology of the Delta Opioid Receptor , the primary target in TuHURA's Antibody Drug Conjugate  and Antibody Peptide Conjugate  technology platform. TAMPA, Fla., April 7, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced the appointment of Bertrand Le Bourdonnec, PhD as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management.Dr. Le Bourdonnec added, \"I am thrilled to join the TuHURA team at this pivotal time in the Company's evolut","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306806265.USD","IE000M9KFDE8.USD","BK4533","LU2237443978.SGD","R","LU0456855351.SGD","HURA","LU1066051498.USD","BK4581","IE00BLSP4452.SGD","LU0321505868.SGD","LU2236285917.USD","LU2420271590.USD","IE00B19Z3B42.SGD","LU1066053197.SGD","IE00B19Z3581.USD","ADC","BK4585","SG9999013999.USD","LU0868494617.USD","BK4588","LU1366333091.USD","LU1894683348.USD","LU1894683264.USD","SG9999002224.SGD","LU0077335932.USD","BK4080","LU2417539215.USD","BK4231","LU0157215616.USD","IE00BLSP4239.USD","LU0225284248.USD","LU2237443549.SGD","LU1883839398.USD","LU2456880835.USD","BK4599","SG9999003800.SGD","LU0170899867.USD","LU0234572021.USD","LU0058720904.USD","LU0289739699.SGD","APC","SGXZ57979304.SGD","LU2237443622.USD","LU0122379950.USD","SG9999001176.USD","SG9999002232.USD","LU0306807586.USD","LU1366192091.USD"],"gpt_icon":1},{"id":"2524554482","title":"TuHURA Biosciences Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524554482","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524554482?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:58","pubTimestamp":1743681480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 03, 2025 07:58 ET (11:58 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA"],"gpt_icon":0},{"id":"2524234995","title":"TuHURA Biosciences price target lowered to $12 from $13 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2524234995","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524234995?lang=en_us&edition=fundamental","pubTime":"2025-04-03 18:15","pubTimestamp":1743675321,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on TuHURA Biosciences (HURA) to $12 from $13 and keeps a Buy rating on the shares following the Q4 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-price-target-lowered-to-12-from-13-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-price-target-lowered-to-12-from-13-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2524187561","title":"TuHURA Biosciences FY24 EPS ($1.21) Up From ($2.47) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2524187561","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524187561?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:13","pubTimestamp":1743509636,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences FY24 EPS ($1.21) Up From ($2.47) YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/44583503/tuhura-biosciences-fy24-eps-1-21-up-from-2-47-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA"],"gpt_icon":0},{"id":"2524190796","title":"Press Release: TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2524190796","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524190796?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:00","pubTimestamp":1743508800,"startTime":"0","endTime":"0","summary":"Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda. MCC Phase 3 trial to be conducted under Special Protocol Assessment . Acquisition of Kineta's Phase 2 ready, VISTA inhibiting antibody targeted for. TAMPA, Fla., April 1, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided financial results for fiscal year 2024 and provided a corporate update.Innate Immune Agonists: TuHURA's IFx technology utilizes a proprietary plasmid DNA or messenger RNA  which, when introduced into or targeted to a tumor, results in the expression of a highly immunogenic gra","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","LU0106261372.USD","BK4531","LU1571399168.USD","SG9999011746.SGD","USJW.SI","LU0265550946.USD","LU1061106388.HKD","IE00BSNM7G36.USD","01698","IE00BYQNZ168.SGD","USAW.SI","LU1066051498.USD","QLD","PFS","NVIW.SI","LU1069347547.HKD","LU0208291251.USD","LU2039709279.SGD","BK4588","PSQ","SQQQ","TSYW.SI","NQmain","QID","MNQmain","BK4534","MRK","LU1929549753.HKD","IE00B12V2V27.USD","SG9999015358.SGD","LU2112291526.USD","IE00B2B36J28.USD","TME","IE000M9KFDE8.USD","TQQQ","LU0266013472.USD","LU0265550359.USD","BK4509","BK4516","SG9999013999.USD","LU1066051225.USD","IE00BN8TJ469.HKD","BK4526",".IXIC","LU1934455194.USD","LU1917777945.USD","BK4232","R"],"gpt_icon":1},{"id":"2518254745","title":"TuHURA Biosciences appoints Craig Tendler to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2518254745","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518254745?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:30","pubTimestamp":1741696254,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences (HURA) has appointed Craig Tendler, M.D. to its Board of Directors effective March 10, 2025. During his tenure at Johnson & John...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-appoints-craig-tendler-to-board-of-directors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-appoints-craig-tendler-to-board-of-directors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2518749844","title":"TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2518749844","media":"ACCESS Newswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518749844?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:05","pubTimestamp":1741694700,"startTime":"0","endTime":"0","summary":"Dr. Tendler oversaw 30 Major Drug Approvals, including worldwide approvals for J&J's transformational treatments in hematologic malignancies, prostate, lung and bladder cancers. Dr. Tendler also oversaw 13 FDA Breakthrough Designations accelerating the early development of promising investigational medicines intended for treatment of serious oncology indications. TAMPA, FL / ACCESS Newswire / March 11, 2025 / TuHURA Biosciences, Inc.  , a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced it has appointed Craig L. Tendler, M.D. to its Board of Directors effective March 10, 2025.Dr. Tendler added, \"TuHURA has established a science-based portfolio of novel complementary technologies and late-stage drug candidates that I believe has the potential to make a significant impact on the immuno-oncology treatment landscape. The data demonstrated to date are promising and underscore the ability of one o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tuhura-biosciences-inc-appoints-craig-120500961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4563","IE00BYQNZ168.SGD","BK4565","BK4139","IE00B12V2V27.USD","LU0359202008.SGD","TME","JNJ","BK4526","IE00BYTNYN87.SGD","BK4203","BK4535","01698","BK4509","BK4531","HURA","BK4225","BK4548","SG9999011746.SGD","BK4571","LU0359201612.USD","LU2039709279.SGD","BK4552","LU1023057109.AUD","GMRE","BK4108"],"gpt_icon":0},{"id":"2518233227","title":"TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2518233227","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518233227?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:00","pubTimestamp":1741611600,"startTime":"0","endTime":"0","summary":"Live webcast fireside chat on Tuesday, March 18th at 8:30 AM PT. TAMPA, FL / ACCESS Newswire / March 10, 2025 / TuHURA Biosciences, Inc.  , a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA, will participate in a fireside chat on Tuesday, March 18, 2025 at 8:30 AM PT at the 37th Annual ROTH Conference being held in Dana Point, CA.In addition to the presentation, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, please visit the conference website.TuHURA Biosciences, Inc.  is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cance","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tuhura-biosciences-inc-present-37th-130000429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","IE00BYQNZ168.SGD","BK4548","BK4526","BK4108","LU2039709279.SGD","ROTH","BK4571","IE00BYTNYN87.SGD","IE00B12V2V27.USD","BK4509","BK4552","LU0359202008.SGD","LU1023057109.AUD","TME","SG9999011746.SGD","BK4563","BK4139","LU0359201612.USD","BK4565","BK4531","01698","HURA"],"gpt_icon":0},{"id":"2516635440","title":"TuHURA Biosciences Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2516635440","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516635440?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:27","pubTimestamp":1741008420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2025 08:27 ET (13:27 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2516680115","title":"HC Wainwright Initiates TuHURA Biosciences at Buy With $13 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2516680115","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516680115?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:20","pubTimestamp":1741004457,"startTime":"0","endTime":"0","summary":"HC Wainwright Initiates TuHURA Biosciences at Buy With $13 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HURA"],"gpt_icon":0},{"id":"2516828386","title":"TuHURA Biosciences initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2516828386","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516828386?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:21","pubTimestamp":1741000864,"startTime":"0","endTime":"0","summary":"H.C. Wainwright initiated coverage of TuHURA Biosciences (HURA) with a Buy rating and $13 price target TuHURA is a clinical-stage biotechnology com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2516968469","title":"Tuhura Biosciences, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2516968469","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516968469?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:16","pubTimestamp":1741000560,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nAZN3H7E64:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2510362858","title":"TuHURA Biosciences Inc  expected to post a loss of 13 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2510362858","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510362858?lang=en_us&edition=fundamental","pubTime":"2025-02-10 19:17","pubTimestamp":1739186229,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Inc  expected to post a loss of13cents a share - Earnings Preview TuHURA Biosciences Inc HURA.OQ HURA.O is expected to report resultson February 12 (estimated) for the period ending","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nL8N3P10VM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HURA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-31","symbol":"HURA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"HURA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-1.37},{"market":"US","date":"2024-10-18","symbol":"HURA","defaultRemindTime":1729258200000,"type":"split","dateTimestamp":1729224000000,"forFactor":35,"toFactor":1,"ratio":35},{"market":"US","date":"2024-10-07","symbol":"HURA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1728273600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HURA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HURA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1741233600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HURA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HURA","date":"2025-05-05","current":-7.897092,"percent":0.606299,"low":-15.284879,"twenty":-10.494894,"median":-8.398148,"eighty":-7.036381,"high":-4.329639,"avg":-8.746903,"sd":2.391961,"marketCap":171227156},"quantilePoints":[{"date":"2024-10-31","current":-8.730961,"twenty":-7.999797,"median":-7.383325,"eighty":-6.996296,"marketCap":255964076},{"date":"2024-11-08","current":-7.555364,"twenty":-8.206244,"median":-7.555364,"eighty":-7.208419,"marketCap":221499291},{"date":"2024-11-15","current":-7.024911,"twenty":-7.675791,"median":-7.239959,"eighty":-7.070789,"marketCap":205948107},{"date":"2024-11-22","current":-7.665321,"twenty":-7.599347,"median":-7.225623,"eighty":-6.910219,"marketCap":140801257},{"date":"2024-11-29","current":-15.010301,"twenty":-7.933971,"median":-7.512354,"eighty":-7.036381,"marketCap":275718282},{"date":"2024-12-06","current":-13.866223,"twenty":-11.098214,"median":-7.555364,"eighty":-7.065054,"marketCap":254703169},{"date":"2024-12-13","current":-12.310277,"twenty":-13.486389,"median":-7.688203,"eighty":-7.082258,"marketCap":226122615},{"date":"2024-12-20","current":-9.152622,"twenty":-13.106555,"median":-8.294564,"eighty":-7.105196,"marketCap":168120904},{"date":"2024-12-27","current":-10.411108,"twenty":-12.712992,"median":-8.730961,"eighty":-7.156808,"marketCap":191237528},{"date":"2025-01-03","current":-9.404319,"twenty":-12.676382,"median":-9.175503,"eighty":-7.225623,"marketCap":172744228},{"date":"2025-01-10","current":-9.541609,"twenty":-12.383498,"median":-9.381438,"eighty":-7.248561,"marketCap":175266042},{"date":"2025-01-17","current":-10.822976,"twenty":-11.486541,"median":-9.518727,"eighty":-7.460742,"marketCap":198802968},{"date":"2025-01-24","current":-10.571279,"twenty":-11.170776,"median":-9.724661,"eighty":-7.521761,"marketCap":194179644},{"date":"2025-01-31","current":-11.325839,"twenty":-11.2987,"median":-9.861951,"eighty":-7.544431,"marketCap":208039858},{"date":"2025-02-07","current":-10.266919,"twenty":-11.2987,"median":-10.022121,"eighty":-7.555364,"marketCap":188588977},{"date":"2025-02-14","current":-10.552406,"twenty":-11.252498,"median":-10.136529,"eighty":-7.621338,"marketCap":193832969},{"date":"2025-02-21","current":-7.603262,"twenty":-11.206135,"median":-9.999239,"eighty":-7.574523,"marketCap":139661309},{"date":"2025-02-28","current":-5.806127,"twenty":-11.137841,"median":-9.861951,"eighty":-7.518625,"marketCap":106650454},{"date":"2025-03-07","current":-4.700198,"twenty":-11.042639,"median":-9.689249,"eighty":-7.174012,"marketCap":86336082},{"date":"2025-03-14","current":-4.561957,"twenty":-10.951113,"median":-9.541609,"eighty":-7.036381,"marketCap":83796785},{"date":"2025-03-21","current":-9.216075,"twenty":-10.928231,"median":-9.438641,"eighty":-6.704264,"marketCap":169286436},{"date":"2025-03-28","current":-8.340548,"twenty":-10.90535,"median":-9.216075,"eighty":-6.852872,"marketCap":153204224},{"date":"2025-04-04","current":-6.636447,"twenty":-10.864163,"median":-9.011547,"eighty":-6.704264,"marketCap":143893470},{"date":"2025-04-11","current":-7.796363,"twenty":-10.722297,"median":-8.730961,"eighty":-6.759947,"marketCap":169043136},{"date":"2025-04-17","current":-8.340296,"twenty":-10.567504,"median":-8.501461,"eighty":-6.795924,"marketCap":180836843},{"date":"2025-04-25","current":-8.521606,"twenty":-10.542452,"median":-8.46117,"eighty":-6.852364,"marketCap":184768079},{"date":"2025-05-02","current":-7.8568,"twenty":-10.498764,"median":-8.409668,"eighty":-7.030646,"marketCap":170353548},{"date":"2025-05-05","current":-7.897092,"twenty":-10.494894,"median":-8.398148,"eighty":-7.036381,"marketCap":171227156}],"updateTime":1746530927536}}}